Testagen
also known as Lys-Glu-Asp-Gly, KEDG
Short tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson bioregulator tradition, proposed as a testicular tissue-specific regulator. Animal models suggest support for testicular function and spermatogenesis. Penetrates cell nuclei and demonstrates specific interaction with DNA and oligonucleotides in vitro, consistent with the bioregulator framework of peptide-mediated gene expression modulation. Evidence remains limited to mechanistic and animal studies; no human clinical trials or regulatory approval.
At a glance
SQ · Abdomen · Cyclical
Primary target — Testicular tissue; proposed nuclear DNA interaction.
Pathway — Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis) [fedoreyeva-2011].
Downstream effect — Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interaction [fedoreyeva-2011].
Origin — Khavinson bioregulator school — isolated from testicular tissue peptide fractions.
Feedback intact — Unknown — no HPG axis data.
| Parameter | Value |
|---|---|
| Typical protocol (anecdotal) | 100–200 mcg / dayNo published human dosing studies; derived from Russian bioregulator practice. |
| Frequency | Once daily or alternate days |
| Cycle length | 10–20 days on, 10–14 days offBioregulator tradition uses pulsed cycles; no controlled data. |
| Evidence basis | Animal mechanistic / in vitro only [fedoreyeva-2011] |
| Route | Subcutaneous |
| Reconstitution | Sterile water or bacteriostatic saline |
| Half-life | Unknown — likely minutes (short peptide) |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- — Active testicular malignancy
- — Hormone-sensitive cancers (no data; theoretical caution)
- — Pregnant or breastfeeding (no data)
- 01Reconstitution
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
- 02Injection site
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
- 03Timing
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
- 04Storage
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
- 05Cycle protocol
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.
Sources
of 41 rendered claims carry a resolvable citation.
- [fedoreyeva-2011]Fedoreyeva 2011 — Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
journal, 2011